logo

Audentes Therapeutics, Inc. (BOLD)



Trade BOLD now with
  Date
  Headline
2/12/2018 8:15:46 AM Audentes Announces Dosing Of First Patient In VALENS, Phase 1/2 Trial Of AT342 For Treatment Of Crigler-Najjar Syndrome
2/6/2018 7:41:40 PM Audentes Therapeutics Announces Selection Of Optimized Clinical Development Candidate For Pompe Disease Program
1/24/2018 7:54:15 PM Audentes Therapeutics Announces Pricing Of Underwritten Public Offering Of 5.75 Mln Shares At $35.00/shr
1/23/2018 4:07:47 PM Audentes Therapeutics Announces Proposed Public Offering Of Common Stock
1/4/2018 7:04:26 AM Audentes Announces Positive Interim Data From First Dose Cohort Of ASPIRO
11/15/2017 11:34:04 AM Wedbush Is Cutting Audentes Therapeutics, Inc. (BOLD) FY17 Estimate To -3.44 From -3.38
11/15/2017 11:33:35 AM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q4 17 Estimate To -0.86 From -0.85
8/10/2017 8:15:04 AM Audentes Therapeutics Q2 Net Loss $22.7 Mln Vs. Net Loss $14.2 Mln Prior Year
5/15/2017 6:59:45 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) 2018 Estimate To -3.21 From -3.19
5/15/2017 6:59:22 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q4 18 Estimate To -0.83 From -0.82
5/15/2017 6:58:52 PM Wedbush Is Lowering Audentes Therapeutics, Inc. (BOLD) Q3 18 Estimate To -0.81 From -0.80